What Researchers Did
Researchers evaluated the efficacy of hyperbaric oxygen therapy as a supplementary treatment for sudden sensorineural hearing loss by comparing outcomes in 68 patients receiving either standard care or standard care plus HBO2.
What They Found
The hyperbaric oxygen therapy group showed a statistically significant improvement in auditory threshold across all frequency groups (P < 0.001), unlike the control group which only improved significantly in the 1,000-2,000 Hertz range (P = 0.01). The rate of hearing gain was more than doubled in the HBO2 group (61.7%) compared to the control group (28.6%), with HBO2 supplementation increasing the effect of pharmacotherapy by 11.5 decibels (P < 0.001).
What This Means for Canadian Patients
For Canadian patients experiencing sudden sensorineural hearing loss, these findings suggest that hyperbaric oxygen therapy could be a valuable supplementary treatment. Integrating HBO2 into existing protocols might lead to significantly better hearing recovery outcomes compared to standard care alone.
Canadian Relevance
This study was conducted in the Slovak Republic and does not have a direct Canadian connection.
Study Limitations
A limitation of this study is its relatively small sample size of 68 patients and its single-center design, which may affect the generalizability of the findings.